Weight Loss Injections Used for Diabetes: The UK Picture

You've seen the headlines: diabetes jabs, weight loss, same drug, so what's actually going on?

You've probably noticed the overlap in the news: medicines originally trialled in people with type 2 diabetes are now showing up in weight-loss clinics. That's not a coincidence or a workaround. The biology is connected. GLP-1 receptor agonists work partly by signalling fullness to the brain and slowing how quickly the stomach empties, effects that reduce appetite as well as lowering blood sugar. Once that weight-reduction effect was measured in trials, manufacturers sought and received separate licences specifically for weight management.

Semaglutide is the clearest example. Ozempic (semaglutide, Novo Nordisk) is licensed for type 2 diabetes. Wegovy (the same molecule, at a higher 2.4mg weekly dose, now up to 7.2mg) holds a distinct UK licence for weight management. The NHS semaglutide medicines page sets out both products clearly. Prescribing Ozempic for weight loss in someone without diabetes would be off-label; that is a separate clinical decision and not something a responsible online pharmacy should be doing routinely. Tirzepatide (Mounjaro) follows a similar story: it holds both a diabetes licence and a weight-management licence, issued separately by the MHRA. The drug is the same; the indication, dose schedule and clinical oversight differ.

If you're asking what the newer injections licensed for both conditions look like in practice, the short answer is: Mounjaro is the one that holds both licences simultaneously in the UK.

The type 1 diabetes question, and where the evidence sits

A question our prescribers hear most weeks is whether these injections are suitable for people with type 1 diabetes who also want to lose weight. Honestly, the evidence here is still developing. Neither Mounjaro nor Wegovy holds a UK licence for type 1 diabetes. The concern is hypoglycaemia: GLP-1 medicines reduce appetite and slow gastric emptying, which can interact unpredictably with insulin dosing in type 1. That doesn't mean research has stopped (trials are ongoing) but right now, off-label use in type 1 is a specialist decision made with a diabetes consultant, not something an online weight-loss service should be initiating. Our page on weight loss injections for type 1 diabetes covers the current evidence in more detail. If you have type 1, talk to your diabetes team first.

For people with type 2 diabetes, the picture is different. Both Mounjaro and Wegovy (injection) are licensed for weight management in adults with a BMI of 30 or above, or 27 and above alongside a weight-related condition, and type 2 diabetes counts as one of those conditions. NICE's appraisal of tirzepatide, TA1026, specifically notes its recommendation for adults with at least one weight-related comorbidity, which includes type 2 diabetes. The key point: your prescriber needs to see the full picture, including your current diabetes medicines, before any weight-loss injection is added. Interactions, hypoglycaemia risk and monitoring frequency all need to be factored in.

Safety realities, what the evidence says and what's still being watched

Both medicines have large safety datasets behind them. Common side effects are gastrointestinal: nausea, loose stools, constipation, and reflux tend to be most noticeable in the early weeks of treatment or after a dose increase, then ease for most people. That picture is consistent across the SURMOUNT trials for tirzepatide and the STEP programme for semaglutide. More serious but uncommon effects include acute pancreatitis, in January 2026 the MHRA issued a Drug Safety Update reminding prescribers and patients to seek urgent medical help for severe, persistent stomach pain that radiates to the back. That update is worth reading in full on the MHRA Yellow Card site, where you can also report any suspected side effects yourself.

There are clear situations where these medicines are not recommended regardless of diabetes status. Pregnancy, breastfeeding and actively trying to conceive all fall into that category. Women of childbearing age using oral contraceptives alongside tirzepatide should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide can reduce how much of the pill is absorbed; this is covered in detail on the NHS England weight-management injections page. Before any surgical procedure, your anaesthetist needs to know you are taking one of these medicines.

Verifying whether a medicine is genuinely appropriate for your situation (including your diabetes management, other prescriptions and medical history) is exactly what a clinical consultation is for. Our page on whether diabetes injections are safe for weight loss goes deeper on the safety evidence.

Getting a legitimate prescription: the route that matters

These are prescription-only medicines. The only lawful route in the UK is a clinical assessment by a registered prescriber who decides whether treatment is appropriate. Sellers offering these injections without that step are operating illegally, and the MHRA has seized large quantities of counterfeit pens from unlicensed sources, some containing insulin rather than the stated medicine. That is not a theoretical risk.

At nume, every consultation is read and decided by a GPhC-registered Independent Prescriber, a real clinician, not automated software. If you order before noon on a working day and your prescriber approves treatment, it leaves the same day and arrives the next working day with DPD, in plain packaging. If you want to understand the broader landscape of what's available, our guide to weight loss injections covers the licensed options side by side. Or if cost is on your mind, the cheap weight loss injections page explains honestly what low prices often mean for medicines like these.

Suitability is a clinical judgement. Check your eligibility with our prescribers, the consultation is free, and you'll get a clear answer either way.